[{"orgOrder":0,"company":"Slayback Pharma","sponsor":"Lupin Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Norethisterone Acetate","moa":"||Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Slayback Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Slayback Pharma \/ Lupin Ltd","highestDevelopmentStatusID":"15","companyTruncated":"Slayback Pharma \/ Lupin Ltd"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Norethisterone Acetate","moa":"||Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Glenmark Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Xiromed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Norethisterone Acetate","moa":"||Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Xiromed","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Softgel Capsule","sponsorNew":"Xiromed \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Xiromed \/ Inapplicable"},{"orgOrder":0,"company":"Martini Hospital Groningen","sponsor":"dr. J.M. Munster, gynaecologist, principal investigator","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Ferrous Fumarate","moa":"Transferrin receptor protein 1; Egl nine homolog 1; Histone deacetylase 8; Alpha-hemoglobin-stabilizing protein; Hemoglobin subunit alpha; Frataxin, mitochondrial; Ferritin heavy chain; Flap endonuclease 1; Endonuclease 8-like 1; Endonuclease 8-like 2; DNA polymerase beta; Ceruloplasmin; Serotransferrin","graph1":"Hematology","graph2":"Phase IV","graph3":"Martini Hospital Groningen","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Martini Hospital Groningen \/ dr. J.M. Munster, gynaecologist, principal investigator","highestDevelopmentStatusID":"11","companyTruncated":"Martini Hospital Groningen \/ dr. J.M. Munster, gynaecologist, principal investigator"},{"orgOrder":0,"company":"Dr. Anil K. Gupta Medicine Professional Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Inapplicable","leadProduct":"Ferrous Fumarate","moa":"Transferrin receptor protein 1; Egl nine homolog 1; Histone deacetylase 8; Alpha-hemoglobin-stabilizing protein; Hemoglobin subunit alpha; Frataxin, mitochondrial; Ferritin heavy chain; Flap endonuclease 1; Endonuclease 8-like 1; Endonuclease 8-like 2; DNA polymerase beta; Ceruloplasmin; Serotransferrin","graph1":"Hematology","graph2":"Undisclosed","graph3":"Dr. Anil K. Gupta Medicine Professional Corporation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dr. Anil K. Gupta Medicine Professional Corporation \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Dr. Anil K. Gupta Medicine Professional Corporation \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals for Palafer

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Dr. Anil K. Gupta Medicine Professional Corporation

                          Country arrow
                          Peptide Process CMC
                          Not Confirmed

                          Dr. Anil K. Gupta Medicine Professional Corporation

                          Country arrow
                          Peptide Process CMC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Vitamins/Minerals/Inorganic Salts

                          Upfront Cash : Inapplicable

                          March 12, 2024

                          Lead Product(s) : Ferrous Fumarate

                          Therapeutic Area : Hematology

                          Highest Development Status : Undisclosed

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : The generic version of Taytulla®1 Capsules, Norethindrone Acetate and Ethinyl Estradiol Capsules and Ferrous Fumarate Capsules, 1 mg/20 mcg, has received approval by the United States Food & Drug Administration.

                          Product Name : Norethindrone Acetate/Ethinyl Estradiol/Ferrous Fumarate-Generic

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          July 29, 2022

                          Lead Product(s) : Norethisterone Acetate,Ethinyl Estradiol,Ferrous Fumarate

                          Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : U.S.FDA has approved Abbreviated New Drug Application for Merzee (Slayback Pharma), an AB-rated generic equivalent of Taytulla® (Allergan), an estrogen/progestin combination oral contraceptive indicated for use by women to prevent pregnancy.

                          Product Name : Merzee

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          July 04, 2022

                          Lead Product(s) : Norethisterone Acetate,Ethinyl Estradiol,Ferrous Fumarate

                          Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                          Highest Development Status : Approved FDF

                          Sponsor : Lupin Ltd

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Martini Hospital Groningen

                          Country arrow
                          Peptide Process CMC
                          Not Confirmed

                          Martini Hospital Groningen

                          Country arrow
                          Peptide Process CMC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Vitamins/Minerals/Inorganic Salts

                          Upfront Cash : Inapplicable

                          March 14, 2022

                          Lead Product(s) : Ferrous Fumarate

                          Therapeutic Area : Hematology

                          Highest Development Status : Phase IV

                          Sponsor : dr. J.M. Munster, gynaecologist, principal investigator

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : Taytulla® is an estrogen/progestin combination oral contraceptive indicated for use by women to prevent pregnancy. Annual market sales for Taytulla® for the twelve month period ending August, 2020 were $157 million, according to IQVIA™.

                          Product Name : Gemmily

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          September 11, 2020

                          Lead Product(s) : Norethisterone Acetate,Ethinyl Estradiol,Ferrous Fumarate

                          Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Isabelle Herter-Aeberli

                          Country arrow
                          Peptide Process CMC
                          Not Confirmed

                          Isabelle Herter-Aeberli

                          Country arrow
                          Peptide Process CMC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Vitamins/Minerals/Inorganic Salts

                          Upfront Cash : Inapplicable

                          June 24, 2019

                          Lead Product(s) : Ferrous Fumarate

                          Therapeutic Area : Hematology

                          Highest Development Status : Undisclosed

                          Sponsor : Antistress AG - Burgerstein Vitamine

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Isabelle Herter-Aeberli

                          Country arrow
                          Peptide Process CMC
                          Not Confirmed

                          Isabelle Herter-Aeberli

                          Country arrow
                          Peptide Process CMC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Vitamins/Minerals/Inorganic Salts

                          Upfront Cash : Inapplicable

                          December 03, 2018

                          Lead Product(s) : Ferrous Fumarate

                          Therapeutic Area : Hematology

                          Highest Development Status : Undisclosed

                          Sponsor : Antistress AG - Burgerstein Vitamine

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          Swiss Federal Institute of Technology

                          Country arrow
                          Peptide Process CMC
                          Not Confirmed

                          Swiss Federal Institute of Technology

                          Country arrow
                          Peptide Process CMC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Vitamins/Minerals/Inorganic Salts

                          Upfront Cash : Inapplicable

                          October 30, 2017

                          Lead Product(s) : Ferrous Fumarate

                          Therapeutic Area : Hematology

                          Highest Development Status : Undisclosed

                          Sponsor : Antistress AG - Burgerstein Vitamine

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          Academisch Medisch Centrum - Universiteit van Amsterdam

                          Country arrow
                          Peptide Process CMC
                          Not Confirmed

                          Academisch Medisch Centrum - Universiteit van Amsterdam

                          Country arrow
                          Peptide Process CMC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Vitamins/Minerals/Inorganic Salts

                          Upfront Cash : Inapplicable

                          September 18, 2014

                          Lead Product(s) : Ferrous Fumarate

                          Therapeutic Area : Hematology

                          Highest Development Status : Phase IV

                          Sponsor : CSL Vifor

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank